Lymphoseek

Chemical Nametechnetium Tc 99m tilmanocept
Dosage FormInjection (intradermal/subcutaneous/subareolar/peritumoral; 92.5 MBq (2.5 mCi) and 250 mcg of technetium Tc 99m tilmanocept)
Drug ClassRadioactive diagnostic agents
SystemBlood
CompanyCardinal Health
Approval Year2013

Indication

  • Indicated with or without scintigraphic imaging for lymphatic mapping using a handheld gamma counter to locate lymph nodes draining a primary tumor site in adult and pediatric patients age one month and older with solid tumors for which this procedure is a component of intraoperative management.
  • Indicated with or without scintigraphic imaging for lymphatic guiding sentinel lymph node biopsy using a handheld gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity, breast cancer or melanoma.
Last updated on 6/23/2022

More on this drug: Clinical Trials

Document TitleYearSource
Lymphoseek (technetium Tc 99m tilmanocept) Prescribing Information.2021Cardinal Health 414, LLC Dublin, OH

Have we missed a study, or would you like to comment on a study?